DW1601
/ Daewon Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 30, 2022
The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial.
(PubMed, Korean J Intern Med)
- "Significant adverse events were not observed in the DW1601 group. DW1601 is superior to DW16011 or P. sidoides in improving symptoms of acute bronchitis."
Clinical • Journal • P3 data • Cough • Pulmonary Disease • Respiratory Diseases
February 07, 2020
Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis
(clinicaltrials.gov)
- P3; N=204; Active, not recruiting; Sponsor: Daewon Pharmaceutical Co., Ltd.
Clinical • Head-to-Head • New P3 trial
1 to 2
Of
2
Go to page
1